Cargando…
Characterisation of an Atrx Conditional Knockout Mouse Model: Atrx Loss Causes Endocrine Dysfunction Rather Than Pancreatic Neuroendocrine Tumour
SIMPLE SUMMARY: ATRX and DAXX mutations occur in 30–40% of pancreatic neuroendocrine tumours (PanNETs), and there are no reports in the literature of any genetically engineered mouse model (GEMM) evaluating the effect of Atrx disruption as a putative driver event on PanNET initiation. We created a n...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406167/ https://www.ncbi.nlm.nih.gov/pubmed/36010860 http://dx.doi.org/10.3390/cancers14163865 |
_version_ | 1784774056259616768 |
---|---|
author | Gaspar, Tiago Bordeira Macedo, Sofia Sá, Ana Soares, Mariana Alves Rodrigues, Daniela Ferreira Sousa, Mafalda Mendes, Nuno Martins, Rui Sousa Cardoso, Luís Borges, Inês Canberk, Sule Gärtner, Fátima Miranda-Alves, Leandro Sobrinho-Simões, Manuel Lopes, José Manuel Soares, Paula Vinagre, João |
author_facet | Gaspar, Tiago Bordeira Macedo, Sofia Sá, Ana Soares, Mariana Alves Rodrigues, Daniela Ferreira Sousa, Mafalda Mendes, Nuno Martins, Rui Sousa Cardoso, Luís Borges, Inês Canberk, Sule Gärtner, Fátima Miranda-Alves, Leandro Sobrinho-Simões, Manuel Lopes, José Manuel Soares, Paula Vinagre, João |
author_sort | Gaspar, Tiago Bordeira |
collection | PubMed |
description | SIMPLE SUMMARY: ATRX and DAXX mutations occur in 30–40% of pancreatic neuroendocrine tumours (PanNETs), and there are no reports in the literature of any genetically engineered mouse model (GEMM) evaluating the effect of Atrx disruption as a putative driver event on PanNET initiation. We created a novel GEMM with Atrx conditional disruption in β cells. We observed that this genetic alteration, per se, was not tumourigenic, but we reported novel roles of Atrx on endocrine function, which resulted in dysglycaemia and the exacerbation of inflammageing (increased pancreatic inflammation and hepatic steatosis). ABSTRACT: ATRX is a chromatin remodeller that maintains telomere homeostasis. Loss of ATRX is described in approximately 10% of pancreatic neuroendocrine tumours (PanNETs) and associated with poorer prognostic features. Here, we present a genetically engineered mouse model (GEMM) addressing the role of Atrx loss (Atrx(KO)) in pancreatic β cells, evaluating a large cohort of ageing mice (for up to 24 months (mo.)). Atrx loss did not cause PanNET formation but rather resulted in worsening of ageing-related pancreatic inflammation and endocrine dysfunction in the first year of life. Histopathological evaluation highlighted an exacerbated prevalence and intensity of pancreatic inflammation, ageing features, and hepatic steatosis in Atrx(KO) mice. Homozygous floxed mice presented hyperglycaemia, increased weights, and glucose intolerance after 6 months, but alterations in insulinaemia were not detected. Floxed individuals presented an improper growth of their pancreatic endocrine fraction that may explain such an endocrine imbalance. A pilot study of BRACO-19 administration to Atrx(KO) mice resulted in telomere instability, reinforcing the involvement of Atrx in the maintenance of β cell telomere homeostasis. Thereby, a non-obese dysglycaemic GEMM of disrupted Atrx is here presented as potentially useful for metabolic studies and putative candidate for inserting additional tumourigenic genetic events. |
format | Online Article Text |
id | pubmed-9406167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94061672022-08-26 Characterisation of an Atrx Conditional Knockout Mouse Model: Atrx Loss Causes Endocrine Dysfunction Rather Than Pancreatic Neuroendocrine Tumour Gaspar, Tiago Bordeira Macedo, Sofia Sá, Ana Soares, Mariana Alves Rodrigues, Daniela Ferreira Sousa, Mafalda Mendes, Nuno Martins, Rui Sousa Cardoso, Luís Borges, Inês Canberk, Sule Gärtner, Fátima Miranda-Alves, Leandro Sobrinho-Simões, Manuel Lopes, José Manuel Soares, Paula Vinagre, João Cancers (Basel) Article SIMPLE SUMMARY: ATRX and DAXX mutations occur in 30–40% of pancreatic neuroendocrine tumours (PanNETs), and there are no reports in the literature of any genetically engineered mouse model (GEMM) evaluating the effect of Atrx disruption as a putative driver event on PanNET initiation. We created a novel GEMM with Atrx conditional disruption in β cells. We observed that this genetic alteration, per se, was not tumourigenic, but we reported novel roles of Atrx on endocrine function, which resulted in dysglycaemia and the exacerbation of inflammageing (increased pancreatic inflammation and hepatic steatosis). ABSTRACT: ATRX is a chromatin remodeller that maintains telomere homeostasis. Loss of ATRX is described in approximately 10% of pancreatic neuroendocrine tumours (PanNETs) and associated with poorer prognostic features. Here, we present a genetically engineered mouse model (GEMM) addressing the role of Atrx loss (Atrx(KO)) in pancreatic β cells, evaluating a large cohort of ageing mice (for up to 24 months (mo.)). Atrx loss did not cause PanNET formation but rather resulted in worsening of ageing-related pancreatic inflammation and endocrine dysfunction in the first year of life. Histopathological evaluation highlighted an exacerbated prevalence and intensity of pancreatic inflammation, ageing features, and hepatic steatosis in Atrx(KO) mice. Homozygous floxed mice presented hyperglycaemia, increased weights, and glucose intolerance after 6 months, but alterations in insulinaemia were not detected. Floxed individuals presented an improper growth of their pancreatic endocrine fraction that may explain such an endocrine imbalance. A pilot study of BRACO-19 administration to Atrx(KO) mice resulted in telomere instability, reinforcing the involvement of Atrx in the maintenance of β cell telomere homeostasis. Thereby, a non-obese dysglycaemic GEMM of disrupted Atrx is here presented as potentially useful for metabolic studies and putative candidate for inserting additional tumourigenic genetic events. MDPI 2022-08-10 /pmc/articles/PMC9406167/ /pubmed/36010860 http://dx.doi.org/10.3390/cancers14163865 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gaspar, Tiago Bordeira Macedo, Sofia Sá, Ana Soares, Mariana Alves Rodrigues, Daniela Ferreira Sousa, Mafalda Mendes, Nuno Martins, Rui Sousa Cardoso, Luís Borges, Inês Canberk, Sule Gärtner, Fátima Miranda-Alves, Leandro Sobrinho-Simões, Manuel Lopes, José Manuel Soares, Paula Vinagre, João Characterisation of an Atrx Conditional Knockout Mouse Model: Atrx Loss Causes Endocrine Dysfunction Rather Than Pancreatic Neuroendocrine Tumour |
title | Characterisation of an Atrx Conditional Knockout Mouse Model: Atrx Loss Causes Endocrine Dysfunction Rather Than Pancreatic Neuroendocrine Tumour |
title_full | Characterisation of an Atrx Conditional Knockout Mouse Model: Atrx Loss Causes Endocrine Dysfunction Rather Than Pancreatic Neuroendocrine Tumour |
title_fullStr | Characterisation of an Atrx Conditional Knockout Mouse Model: Atrx Loss Causes Endocrine Dysfunction Rather Than Pancreatic Neuroendocrine Tumour |
title_full_unstemmed | Characterisation of an Atrx Conditional Knockout Mouse Model: Atrx Loss Causes Endocrine Dysfunction Rather Than Pancreatic Neuroendocrine Tumour |
title_short | Characterisation of an Atrx Conditional Knockout Mouse Model: Atrx Loss Causes Endocrine Dysfunction Rather Than Pancreatic Neuroendocrine Tumour |
title_sort | characterisation of an atrx conditional knockout mouse model: atrx loss causes endocrine dysfunction rather than pancreatic neuroendocrine tumour |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406167/ https://www.ncbi.nlm.nih.gov/pubmed/36010860 http://dx.doi.org/10.3390/cancers14163865 |
work_keys_str_mv | AT gaspartiagobordeira characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT macedosofia characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT saana characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT soaresmarianaalves characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT rodriguesdanielaferreira characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT sousamafalda characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT mendesnuno characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT martinsruisousa characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT cardosoluis characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT borgesines characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT canberksule characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT gartnerfatima characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT mirandaalvesleandro characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT sobrinhosimoesmanuel characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT lopesjosemanuel characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT soarespaula characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour AT vinagrejoao characterisationofanatrxconditionalknockoutmousemodelatrxlosscausesendocrinedysfunctionratherthanpancreaticneuroendocrinetumour |